What is the recommended initial management approach for type 1 diabetes mellitus?

Approach to Type 1 Diabetes Mellitus and Management

Initial Insulin Regimen

Start all newly diagnosed type 1 diabetes patients on multiple daily injections (MDI) consisting of 3–4 injections per day using insulin analogs—specifically long-acting basal insulin once daily plus rapid-acting insulin before each meal—or alternatively continuous subcutaneous insulin infusion (CSII) via pump. 1, 2, 3

Why Insulin Analogs Over Human Insulin

• Long-acting basal analogs (glargine, detemir, degludec) deliver flatter, more constant plasma profiles than NPH insulin and significantly reduce hypoglycemia risk, particularly nocturnal episodes. 4, 1, 5
• Rapid-acting prandial analogs (aspart, lispro, glulisine) have faster onset, higher peak, and shorter duration than regular human insulin, better matching postprandial glucose excursions while lowering hypoglycemia risk. 4, 1, 3
• The DCCT demonstrated that intensive therapy reduced microvascular complications by 50% but caused 62 severe hypoglycemia episodes per 100 patient-years with older human insulins; analogs mitigate this risk. 4, 2

Initial Insulin Dosing Algorithm

Step 1: Calculate Total Daily Dose (TDD)

• Start with 0.5 units/kg/day for metabolically stable patients (acceptable range 0.4–1.0 units/kg/day). 1, 3
• Higher doses approaching 1.0 units/kg/day are required during puberty, pregnancy, or acute illness. 1, 3
• Lower doses of 0.2–0.6 units/kg/day for young children or those in the "honeymoon period" with residual endogenous insulin production. 1
• Higher weight-based dosing than standard 0.5 units/kg/day for patients presenting with diabetic ketoacidosis. 1

Step 2: Split Between Basal and Prandial

• Allocate 50% of TDD as basal insulin administered once daily at the same time each day. 1, 3
• Allocate 50% of TDD as prandial insulin divided across three meals. 1, 3
• Note: The 2024 ADA guidelines allow 30–50% basal, but the 50/50 split is the most commonly recommended starting point. 4, 1

Step 3: Basal Insulin Administration

• Administer long-acting analog (glargine, detemir, or degludec) once daily at the same time every day. 1, 6
• Inject subcutaneously into abdomen, thigh, or deltoid; rotate injection sites within the same region to prevent lipohypertrophy. 1, 6
• Never inject into areas of lipodystrophy as this causes erratic absorption and hyperglycemia. 6

Step 4: Prandial Insulin Administration

• Administer rapid-acting analog 0–15 minutes before each meal. 1, 3
• Faster-acting insulin aspart provides superior postprandial glucose coverage compared to standard rapid-acting analogs. 1

Essential Patient Education Components

All patients must be taught to match prandial insulin doses to three factors: 2, 3, 5

1. Carbohydrate intake (carbohydrate counting is foundational)
2. Premeal blood glucose level
3. Anticipated physical activity

Additional education requirements: 3

• Correction dose calculation based on concurrent glycemia and glycemic trends
• Sick-day management protocols
• Glucagon prescription for all patients, with family/caregivers trained on administration for severe hypoglycemia

Basal Insulin Titration Protocol

• Re-evaluate basal insulin every 3 days based on fasting glucose patterns. 1
• Target fasting glucose: 80–130 mg/dL. 1
• Target postprandial glucose: <180 mg/dL. 2
• Target HbA1c: <7% (53 mmol/mol) for most nonpregnant adults. 5

Advanced Insulin Delivery Options

Automated Insulin Delivery (AID) Systems

• AID systems should be considered for all adults with type 1 diabetes to improve time in range, reduce HbA1c, and minimize hypoglycemia. 4, 3
• Hybrid closed-loop AID systems are superior to sensor-augmented pump therapy alone for increasing time in range and reducing hypoglycemia. 4

Continuous Subcutaneous Insulin Infusion (CSII)

• Insulin pump therapy is equally effective as MDI with no systematic differences in HbA1c or severe hypoglycemia rates. 2
• CSII offers modest advantages for lowering HbA1c and reducing severe hypoglycemia in children and adults. 4
• Sensor-augmented pumps with threshold suspend features reduce nocturnal hypoglycemia without increasing HbA1c. 2

Monitoring Strategy

• Continuous glucose monitoring (CGM) should be considered for all patients, particularly those with hypoglycemia unawareness or frequent hypoglycemic episodes. 3, 5
• For patients with glycemic variability, combine CGM results with self-monitoring of blood glucose (SMBG). 7
• Increase frequency of blood glucose monitoring during illness, exercise, or dose adjustments. 1, 6

Reassessment Schedule

• Re-evaluate insulin treatment plans every 3–6 months and adjust based on insulin-taking behavior, cost considerations, and factors impacting treatment choice. 4, 3

Critical Pitfalls to Avoid

• Never administer basal insulin intravenously or via insulin pump (for glargine specifically). 6
• Never dilute or mix insulin glargine with any other insulin or solution. 6
• Avoid intramuscular injections, especially with long-acting insulins, as this causes severe hypoglycemia due to rapid absorption. 1, 7
• Do not abruptly discontinue oral medications (in type 2 diabetes transitioning to insulin) due to risk of rebound hyperglycemia. 7
• When switching from twice-daily NPH to once-daily glargine, start with 80% of total NPH dose to reduce hypoglycemia risk. 6
• When switching from once-daily TOUJEO (U-300) to glargine (U-100), start with 80% of TOUJEO dose. 6

Special Population Adjustments

• Puberty: Insulin requirements often rise to ≈1.0 units/kg/day or higher. 1, 3
• Pregnancy: Higher insulin doses needed throughout gestation. 1, 3
• Medical illness (infections, inflammation): May require higher insulin doses. 1
• Menses: May require higher insulin doses. 1